Fig. 7
From: AGGF1-primed endothelial progenitor cells alleviate ischaemia-reperfusion injury in diabetic hearts
NRF2 is required for AGGF1-primed EPCs therapy. (A) Left ventricular ejection fraction (LVEF, n = 6). (B) Left ventricular fractional shortening (LVFS, n = 6). (C) Representative images of echocardiographic analysis for mice from Sham, I/R + PBS, I/R + EPCs, I/R + AGGF1-EPCs, I/R + AGGF1-EPCs-siNRF2. (D–E) Representative images for immunostaining with an anti-GFP antibody (EPCs homing evaluation) and anti-CD31 antibody (angiogenesis evaluation), n = 6. Data are mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001. ns, not significant.
